925903-31-7

Basic information

• Product Name: 1-Azetidinepropanol
• Synonyms: 1-Azetidinepropanol
• CAS NO: 925903-31-7
• Molecular Formula: C6H13NO
• Molecular Weight: 115.18
• Mol File: 925903-31-7.mol

Chemical Properties

• Boiling Point: 200.4±23.0 °C(Predicted)
• Appearance: /
• Density: 1.013±0.06 g/cm3(Predicted)
• PKA: 15.02±0.10(Predicted)
• CAS DataBase Reference: 1-Azetidinepropanol(CAS DataBase Reference)
• NIST Chemistry Reference: 1-Azetidinepropanol(925903-31-7)
• EPA Substance Registry System: 1-Azetidinepropanol(925903-31-7)

Safety Data

• Hazardous Substances Data: 925903-31-7(Hazardous Substances Data)

Usage

Uses

Used in Organic Synthesis:
1-Azetidinepropanol is used as a building block for the synthesis of complex organic molecules, leveraging its unique azetidine ring structure to facilitate the formation of desired products.
Used in Pharmaceutical Industry:
1-Azetidinepropanol is used as a precursor in the development of pharmaceuticals, contributing to the creation of new drugs with potential therapeutic applications.
Used in Agrochemical Industry:
1-Azetidinepropanol is used as a precursor in the synthesis of agrochemicals, playing a role in the development of new pesticides and other agricultural chemicals.
Used as a Chiral Auxiliary in Asymmetric Synthesis:
1-Azetidinepropanol is used as a chiral auxiliary to control the stereochemistry of reactions, enabling the production of enantiomerically pure compounds, which is crucial in the synthesis of biologically active molecules.
Used in Corrosion Inhibition:
1-Azetidinepropanol has potential industrial applications as a corrosion inhibitor, helping to protect materials from degradation in various industrial settings.
Used in Polymer and Surfactant Production:
1-Azetidinepropanol is used as a component in the production of polymers and surfactants, contributing to the development of new materials with specific properties for various applications.
Used in Material Science:
1-Azetidinepropanol has been studied for its potential use in the development of new materials with specific properties, indicating its versatility and potential in advancing material science research.

Relevant articles and documents

8-[6-[3-(AMINO)PROPOXY]-3-PYRIDYL]-1 -ISOPROPYL-IMIDAZO[4,5-C]QUINOLIN-2-ONE DERIVATIVES AS SELECTIVE MODULATORS OF ATAXIA TELANGIECTASIA MUTATED (ATM) KINASE FOR THE TREATMENT OF CANCER

The specification generally relates to compounds of Formula (I): and pharmaceutically acceptable salts thereof, where Rl, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also discloses the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.

IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where x, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of compounds of Formula (I) and salts thereof to treat or prevent ATM mediated disease, including cancer. The specification further relates to pharmaceutical compositions comprising substituted imidazo[4,5-c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; and intermediates useful in such manufacture.

IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER

The specification generally relates to compounds of Formula (I) and pharmaceutically acceptable salts thereof, where Q, R1, R2, R3, R4 and R5 have any of the meanings defined herein. The specification also relates to the use of such compounds and salts thereof to treat or prevent ATM kinase mediated disease, including cancer. The specification further relates to crystalline forms of compounds of imidazo[4,5- c]quinolin-2-one compounds and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising such compounds and salts; kits comprising such compounds and salts; methods of manufacture of such compounds and salts; intermediates useful in the manufacture of such compounds and salts; and to methods of treating ATM kinase mediated disease, including cancer, using such compounds and salts.

6-[(SUBSTITUTED)PHENYL]TRIAZOLOPYRIMIDINES AS ANTICANCER AGENTS

This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.